vTv Therapeutics Inc. — Form 10-Q Summary
Reporting period: Quarter and six months ended June 30, 2023. vTv is a clinical-stage pharmaceutical company developing small-molecule drug candidates for metabolic and inflammatory diseases. Its lead program is cadisegliatin (TTP399), intended as an adjunct to insulin for type 1 diabetes. The interim financial statements are unaudited.
Financial results and position
| Metric | Q2 2023 | Six months 2023 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $4.7 million | $8.6 million |
| General and administrative expense | $3.3 million | $6.8 million |
| Net loss attributable to vTv Therapeutics Inc. | $5.6 million | $10.1 million |
| Basic and diluted loss per Class A share | $0.07 | $0.12 |
- At June 30, cash and cash equivalents were $12.6 million, versus $12.1 million at December 31, 2022. Long-term investments were $8.0 million, including $3.8 million in Reneo stock and $4.2 million in Anteris preferred stock.
- Six-month operating cash use was $11.3 million, compared with $0.3 million in the prior-year period; financing provided $11.8 million, chiefly from early collection of the G42 promissory note. Cash increased $0.5 million during the period.
- Total liabilities were $28.8 million, including $18.7 million of contract liabilities. No notes payable remained at June 30; lease liabilities totaled $0.4 million. Stockholders’ deficit was $25.3 million and accumulated deficit was $280.8 million.
- Margins are not meaningful because the company reported no revenue in 2023 and has no product sales. The filing reports no material interest-rate or foreign-currency exposure.
Changes versus the prior comparable period
- Q2 revenue was effectively unchanged from the prior-year quarter’s $9,000. Six-month revenue fell from $2.0 million to zero; the 2022 amount principally reflected a Huadong license-agreement milestone and related transaction-price adjustment.
- Q2 R&D expense rose $2.5 million, mainly from cadisegliatin drug-product and trial-preparation costs. Six-month R&D increased $3.3 million for similar reasons.
- Q2 G&A expense increased $1.5 million, while six-month G&A declined $0.4 million, principally due to lower legal and severance costs, partly offset by higher payroll and other costs.
- Six-month net loss attributable to vTv was nearly unchanged from 2022 ($10.1 million versus $10.2 million), despite higher operating expenses, as other income improved. The 2023 period included a $2.4 million unrealized Reneo investment gain; 2022 included a $3.4 million unrealized loss. Q2 2023 other income also included investment and warrant fair-value gains.
Outlook, risks and notable items
- Going concern: Management said June 30 cash was expected to fund operations only into the third quarter of 2023. Its plan to fund operations into the second quarter of 2024 depends on additional financing, partnering or licensing transactions, and the company stated that substantial doubt exists about its ability to continue as a going concern.
- Potential funding sources include direct equity investment, monetization or licensing of programs, up to $37.3 million remaining under the Cantor ATM facility, and approximately $35.9 million remaining under the Lincoln Park purchase agreement. Availability depends in part on share price and trading volume; equity financing could dilute shareholders. No shares were sold under either facility in the first half of 2023.
- Management said it was in active discussions regarding financing, partnering and licensing for cadisegliatin but gave no assurance of completion. It expected to initiate cadisegliatin study activities in the second half of 2023 and said it had FDA alignment on trial designs and the primary endpoint. Clinical, regulatory, enrollment, financing and commercialization outcomes remain uncertain.
- The Cogna/G42 collaboration’s clinical trials had not commenced by June 30, 2023. The company recognized no related collaboration revenue in the first half and reported $18.7 million in contract liabilities. Following FDA approval of cadisegliatin, G42 may elect a $30 million cash payment or stock issuance, subject to agreement terms; this is contingent, not a current payment obligation.
- Nasdaq granted an extension through December 18, 2023 to regain minimum-bid compliance. The extension was based on the company’s representation that it would obtain shareholder approval by October 30 and complete a 1-for-10 to 1-for-20 reverse stock split no later than November 22, 2023.
- The company reported no material legal proceedings and no material changes to previously disclosed risk factors. A potential obligation under its related-party tax receivable agreement is not recorded because no triggering exchanges had occurred.
Important facts for investors to verify
- Whether the company secured financing sufficient to support operations and planned cadisegliatin trials beyond the stated cash runway.
- Whether cadisegliatin study activities began as anticipated, and the status, cost and timing of trials and FDA interactions.
- Whether the Nasdaq bid-price requirements and reverse-split conditions were satisfied by the specified deadlines.
- How much capital can actually be raised through ATM or Lincoln Park facilities, and the resulting dilution and share count.
- Whether Reneo investment gains or losses and other non-operating items materially affect reported results in subsequent periods.